Orion Oyj (OTCMKTS:ORINY - Get Free Report) was the target of a large increase in short interest in March. As of March 31st, there was short interest totalling 5,000 shares, an increase of 1,566.7% from the March 15th total of 300 shares. Approximately 0.0% of the shares of the stock are short sold. Based on an average trading volume of 1,600 shares, the short-interest ratio is currently 3.1 days.
Orion Oyj Stock Performance
ORINY stock remained flat at $28.19 during trading on Friday. The company had a trading volume of 320 shares, compared to its average volume of 3,026. The company has a current ratio of 2.42, a quick ratio of 1.41 and a debt-to-equity ratio of 0.25. The firm's fifty day moving average is $28.61 and its two-hundred day moving average is $25.84. Orion Oyj has a twelve month low of $17.50 and a twelve month high of $31.10. The stock has a market capitalization of $7.96 billion, a P/E ratio of 22.37 and a beta of 0.15.
Orion Oyj (OTCMKTS:ORINY - Get Free Report) last announced its earnings results on Tuesday, February 25th. The company reported $0.28 earnings per share (EPS) for the quarter. The business had revenue of $463.41 million during the quarter. Orion Oyj had a net margin of 23.01% and a return on equity of 39.49%. On average, analysts expect that Orion Oyj will post 1.18 earnings per share for the current year.
Orion Oyj Increases Dividend
The firm also recently announced a dividend, which will be paid on Tuesday, April 29th. Stockholders of record on Monday, April 7th will be issued a $0.4478 dividend. This is an increase from Orion Oyj's previous dividend of $0.24. The ex-dividend date of this dividend is Monday, April 7th. Orion Oyj's payout ratio is presently 24.00%.
Analyst Upgrades and Downgrades
Separately, Nordea Equity Research cut shares of Orion Oyj to a "hold" rating in a research note on Tuesday, February 4th.
Read Our Latest Stock Report on Orion Oyj
About Orion Oyj
(
Get Free Report)
Orion Oyj develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients (APIs) in Finland, Scandinavia, rest of Europe, North America, and internationally. The company provides prescription drugs and self-care products, which includes Nubeqa for the treatment of prostate cancer; Precedex, Dexdor, and Precedex for human use; Burana for inflammatory pain; Divina series for menopausal symptoms; Trexan for rheumatoid arthritis and cancer; Stalevo, Entacapone, and Comtess/Comtan for Parkinson's disease; Biosimilars for rheumatoid arthritis and inflammatory bowel diseases; and Simdax for acute decompensated heart failure, as well as Fareston for breast cancer.
Featured Stories
Before you consider Orion Oyj, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Orion Oyj wasn't on the list.
While Orion Oyj currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
